Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2011 to 2025 of 9090 results

  1. Diverticular disease

    Awaiting development Reference number: GID-QS10086 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Thyroid disease

    Awaiting development Reference number: GID-QS10088 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Osteoporosis

    In development Reference number: GID-QS10188 Expected publication date: TBC

    Quality standard
    In development

  4. Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

    Awaiting development Reference number: GID-TA10717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development Reference number: GID-TA11036 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Adrenal dysfunction

    Awaiting development Reference number: GID-QS10038 Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Semaglutide for treating type 2 diabetes [ID1450]

    Awaiting development Reference number: GID-TA10438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Pancreatitis (including acute pancreatitis)

    Awaiting development Reference number: GID-QS10085 Expected publication date: TBC

    Quality standard
    Awaiting development

  9. Tinnitus

    Awaiting development Reference number: GID-QS10091 Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Sleep disordered breathing

    Awaiting development Reference number: GID-QS10096 Expected publication date: TBC

    Quality standard
    Awaiting development

  11. CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]

    Awaiting development Reference number: GID-TA11182 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Prevention of dementia

    Awaiting development Reference number: GID-QS10109 Expected publication date: TBC

    Quality standard
    Awaiting development

  13. Social work interventions for adults with complex needs (including learning disabilities) and mental health needs

    Awaiting development Reference number: GID-QS10148 Expected publication date: TBC

    Quality standard
    Awaiting development

  14. PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]

    Awaiting development Reference number: GID-TA10885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Gantenerumab for treating early Alzheimer's disease [TSID10668]

    Awaiting development Reference number: GID-TA11072 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development